New therapy for advanced breast cancer patients


The National Institute for Health and Care Excellence has overturned its draft rejection of Keytruda (pembrolizumab) and has said women can take the immunotherapy drug alongside chemotherapy.

The drug is for women with incurable secondary triple negative breast cancer. It aims to slow disease progression – buying patients extra time.

Baroness Delyth Morgan, chief executive of Breast Cancer Now, said it was “absolutely fantastic news for around 100 patients” every year with the disease.

She added: “Following its worrying provisional rejection by Nice earlier this year, the reversal of this decision now brings hope to eligible women.

“It could bring precious additional time before their disease progresses, and more months to live and spend time with loved ones and doing what matters most to them.”




Read original article here

Denial of responsibility! TechnoCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment